NVS Jan 2025 100.000 call
| Previous close | 11.15 |
| Open | 11.10 |
| Bid | 10.30 |
| Ask | 14.50 |
| Strike | 100.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.10 - 11.16 |
| Contract range | N/A |
| Volume | |
| Open interest | 205 |
ZacksFDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
ZacksNovartis' (NVS) Shareholders Approve Sandoz Separation
Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.
GlobeNewswireSandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolioBasel, September 18, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today ann
